Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases

Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases

Abstract Introduction This study aims to evaluate the ocular and systemic safety profiles of intravitreal biosimilar ranibizumab Ranieyes (Lupin Pharmaceuticals, Mumbai, India) in real-world clinical settings across multiple chorioretinal vascular diseases, including neovascular age-related macular...

Full description

Saved in:
Bibliographic Details
Main Authors: Debdulal Chakraborty, Tushar Kanti Sinha, Sourav Sinha, Aniruddha Maiti, Angshuman Mukherjee, Krishnendu Nandi, Sudipta Das, Saptorshi Majumdar, Dinesh Rungta, Ranabir Bhattacharya
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-11-01
Series:Ophthalmology and Therapy
Subjects:
Ranibizumab
Biosimilar
Chorioretinal vascular disease
Safety profile
Intravitreal injection
Real-world study
Online Access:https://doi.org/10.1007/s40123-024-01065-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40123-024-01065-z

Similar Items